{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-017786","form_type":"8-K","ticker":"TCMD","cik":"0001027838","company_name":"TACTILE SYSTEMS TECHNOLOGY INC","filed_at":"2023-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.941274+00:00","generated_at":"2026-06-08T18:53:31.676969+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Tactile Medical Q3 revenue $69.6M (+7% YoY); net income $22.3M vs loss; updates FY guidance","bullets":["Revenue $69.6M, up 7% YoY; lymphedema +15%, airway clearance -36%.","Net income $22.3M ($0.94 diluted EPS) vs loss of $2.3M ($0.11 loss) in Q3 2022.","Adjusted EBITDA $7.7M vs $7.2M; operating income $8.0M vs loss of $1.6M.","FY2023 revenue guidance narrowed to $273-277M from $274-278M, ~11-12% growth.","Sherri Ferstler appointed SVP Sales; Vindell Washington, M.D. added to Board."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-017786","json":"https://secwatch.observer/filing/0001558370-23-017786.json","markdown":"https://secwatch.observer/filing/0001558370-23-017786.md","text":"https://secwatch.observer/filing/0001558370-23-017786.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1027838/000155837023017786/0001558370-23-017786-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1027838/000155837023017786/tcmd-20231106x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T18:53:31.676969+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8506e4b6385dedc6ede91c3f63b9c987c217290b","claim":"TACTILE SYSTEMS TECHNOLOGY INC reported third quarter ended September 30, 2023 results: revenue $69.6 million, net income $22.3 million, EPS $0.94 per diluted share. Guidance reaffirmed.","evidence_excerpt":"with chronic disorders , today reported financial results for the third quarter ended September 30, 2023. Third Quarter 2023 Summary: ● Revenue increased 7% year-over-year to $69.6 million, compared to $65.3 million in third quarter 2022 ● Lymphedema revenue increased 15% ● Airway clearance revenue decreased 36% ● Operating income of $8.0 million, compared to","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1027838/000155837023017786/0001558370-23-017786-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Revenue","value":"$69.6 million"},{"label":"Net income","value":"$22.3 million"},{"label":"EPS","value":"$0.94 per diluted share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"c7820edd4e2ba021c5b099ee2e27bcc4517deee3","claim":"TACTILE SYSTEMS TECHNOLOGY INC reported nine months ended September 30, 2023 results: revenue $196.8 million, net income $20.3 million, EPS $0.88 per diluted share.","evidence_excerpt":"Total revenue for the nine months ended September 30, 2023, increased $23.9 million, or 13.8%, to $196.8 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1027838/000155837023017786/0001558370-23-017786-index.htm","confidence":0.97,"family_label":"Earnings Releases","details":[{"label":"Period","value":"nine months ended September 30, 2023"},{"label":"Revenue","value":"$196.8 million"},{"label":"Net income","value":"$20.3 million"},{"label":"EPS","value":"$0.88 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}